Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM

Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension.

Koulava A, Sannani A, Levine A, Gupta CA, Khanal S, Frishman W, Bodin R, Wolf DC, Aronow WS, Lanier GM

Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.

Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA

Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.

Sanon NT, GagnĂŠ J, Wolf DC, Aboulamer S, Bosoi CM, Simard A, Messiet E, Desgent S, Carmant L

Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.

Afzali A, Ciorba MA, Schwartz DA, Sharaf M, Fourment C, Ritter T, Wolf DC, Shafran I, Randall CW, Kane SV

Response to Loomis et al Comment on Boobis et al.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.

Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG

Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC

Response to letter to the editor from Chappelle, Spence, and Tury concerning Wolf et al. 2016: Illustrative case using the RISK21 roadmap and matrix: prioritization for evaluation of chemicals found in drinking water. 2016, Crit. Rev. Toxicol. Vol 46: 43-53.

Wolf DC, Embry MR

A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.

Paul Friedman K, Papineni S, Marty MS, Yi KD, Goetz AK, Rasoulpour RJ, Kwiatkowski P, Wolf DC, Blacker AM, Peffer RC

Reply.

Wolf DC

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group

Biosimilars in Crohn's Disease and Ulcerative Colitis.

Wolf DC

Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.

Lai HM, Pawar R, Wolf DC, Aronow WS